| Attention deficit hyperactivity disorder
Quillivant XR vs Jornay PM
Side-by-side clinical, coverage, and cost comparison for attention deficit hyperactivity disorder.Deep comparison between: Quillivant vs Jornay Pm with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsJornay Pm has a higher rate of injection site reactions vs Quillivant based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Jornay Pm but not Quillivant, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Quillivant
Jornay Pm
At A Glance
Oral
Daily
CNS stimulant
Oral
Daily
CNS stimulant
Indications
- Attention deficit hyperactivity disorder
- Attention deficit hyperactivity disorder
Dosing
Attention deficit hyperactivity disorder Starting dose 20 mg once daily in the morning for patients 6 years and above; may titrate weekly in increments of 10 mg to 20 mg; daily doses above 60 mg have not been studied and are not recommended.
Attention deficit hyperactivity disorder 20 mg once daily orally in the evening (between 6:30 p.m. and 9:30 p.m.) as the starting dose for patients 6 years and older; titrate weekly in increments of 20 mg up to a maximum of 100 mg/day.
Contraindications
- Hypersensitivity to methylphenidate or other components of QUILLIVANT XR
- Concomitant or recent (within 14 days) use of monoamine oxidase inhibitors (MAOIs)
- History of hypersensitivity to methylphenidate or other components of JORNAY PM
- Concomitant treatment with monoamine oxidase (MAO) inhibitors, or within 14 days following discontinuation of an MAO inhibitor
Adverse Reactions
Most common (>=2%) affect lability, excoriation, initial insomnia, tic, decreased appetite, vomiting, motion sickness, eye pain, rash
Postmarketing pancytopenia, thrombocytopenia, angina pectoris, bradycardia, severe hepatocellular injury, angioedema, anaphylactic reactions, rhabdomyolysis, convulsion, dyskinesia, serotonin syndrome, hallucinations, mania, priapism, alopecia, Raynaud's phenomenon
Most common (>=5%) Any insomnia, decreased appetite, headache, vomiting, nausea, psychomotor hyperactivity, affect lability or mood swings
Serious Hypersensitivity reactions (angioedema, anaphylaxis), hypertensive crisis with MAO inhibitors, serious cardiac events, psychiatric adverse reactions, priapism, peripheral vasculopathy including Raynaud's phenomenon, long-term suppression of growth in pediatric patients
Postmarketing Pancytopenia, thrombocytopenia, angina pectoris, bradycardia, severe hepatic injury, rhabdomyolysis, convulsion, serotonin syndrome, hallucinations, mania, priapism, alopecia, Raynaud's phenomenon
Pharmacology
Methylphenidate is a CNS stimulant that blocks reuptake of norepinephrine and dopamine into the presynaptic neuron and increases the release of these monoamines into the extraneuronal space; the mode of therapeutic action in ADHD is not fully known.
CNS stimulant; methylphenidate is thought to block the reuptake of norepinephrine and dopamine into the presynaptic neuron and increase the release of these monoamines into the extraneuronal space, though the exact mode of therapeutic action in ADHD is not known.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Quillivant
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (10/12)
Jornay Pm
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (1/12)
UnitedHealthcare
Quillivant
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (1/8)
Jornay Pm
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (4/8) · Qty limit (4/8)
Humana
Quillivant
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (3/3)
Jornay Pm
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Quillivant.
No savings programs available for Jornay Pm.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
QuillivantView full Quillivant profile
Jornay PmView full Jornay Pm profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.